Relapsed/Refractory Non-Hodgkin Lymphoma
Oncology·MeSH: Lymphoma, Non-Hodgkin
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
4 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(3)
Phase 4(1)
| Drug | Company |
|---|---|
| BMS-986458 | BRISTOL MYERS SQUIBB CO (BMY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed/Refractory Non-Hodgkin Lymphoma?
BioSniper tracks 4 drugs in development for Relapsed/Refractory Non-Hodgkin Lymphoma across 1 company.
How many clinical trials target Relapsed/Refractory Non-Hodgkin Lymphoma?
There are 1 clinical trial targeting Relapsed/Refractory Non-Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Relapsed/Refractory Non-Hodgkin Lymphoma?
The estimated prevalence of Relapsed/Refractory Non-Hodgkin Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Relapsed/Refractory Non-Hodgkin Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis